lewista's glycopeptide [28 articles] Export

Recent papers added to lewista's library classified by the tag glycopeptide. You can also see everyone's glycopeptide.

	Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections [My Copy] Annals of Clinical Microbiology and Antimicrobials, Vol. 6 (30 October 2007), 13. by Hui-Min Neoh, Satoshi Hori, Mitsutaka Komatsu, et al.Toyoko Oguri, Fumihiko Takeuchi, Longzhu Cui, Keiichi Hiramatsu posted to glycopeptide heteroresistance mrsa by lewista on 2008-12-05 16:47:06 as
	Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. [My Copy] Antimicrobial agents and chemotherapy, Vol. 46, No. 5. (May 2002), pp. 1492-1502. by G. Sakoulas, G. M. Eliopoulos, R. C. Moellering, et al.C. Wennersten, L. Venkataraman, R. P. Novick, H. S. Gold posted to glycopeptide mrsa quorum by lewista on 2008-12-01 19:54:53 as
	Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. [My Copy] Antimicrobial agents and chemotherapy, Vol. 50, No. 9. (September 2006), pp. 3039-3047. by B. P. Howden, P. D. Johnson, P. B. Ward, T. P. Stinear, J. K. Davies posted to glycopeptide heteroresistance mrsa by lewista on 2008-12-01 17:03:50 as along with 1 person gwenknight
	Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. [My Copy] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 36, No. 4. (15 February 2003), pp. 429-439. by S. K. Fridkin, J. Hageman, L. K. McDougal, et al.J. Mohammed, W. R. Jarvis, T. M. Perl, F. C. Tenover, posted to glycopeptide mrsa by lewista on 2008-12-01 16:02:31 as
	Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. [My Copy] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 46, No. 2. (15 January 2008), pp. 193-200. by A. Soriano, F. Marco, J. A. Martínez, et al.E. Pisos, M. Almela, V. P. Dimova, D. Alamo, M. Ortega, J. Lopez, J. Mensa posted to glycopeptide mrsa by lewista on 2008-12-01 15:55:46 as
	High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. [My Copy] Archives of internal medicine, Vol. 166, No. 19. (23 October 2006), pp. 2138-2144. by L. K. Hidayat, D. I. Hsu, R. Quist, K. A. Shriner, A. Wong-Beringer posted to glycopeptide pharmacokinetics by lewista on 2008-11-20 15:34:55 as
	The comparative efficacy and safety of teicoplanin and vancomycin. [My Copy] The Journal of antimicrobial chemotherapy, Vol. 38, No. 6. (December 1996), pp. 1113-1114. by J. Cobo, J. Fortún posted to glycopeptide pharmacokinetics by lewista on 2008-11-20 15:29:47 as
	The comparative efficacy and safety of teicoplanin and vancomycin. [My Copy] The Journal of antimicrobial chemotherapy, Vol. 37, No. 2. (February 1996), pp. 209-222. by M. J. Wood posted to glycopeptide pharmacokinetics by lewista on 2008-11-20 15:20:24 as
	Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. [My Copy] The Journal of antimicrobial chemotherapy, Vol. 51, No. 4. (April 2003), pp. 971-975. by F. Pea, L. Brollo, P. Viale, F. Pavan, M. Furlanut posted to glycopeptide pharmacokinetics by lewista on 2008-11-20 15:13:19 as
	Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. [My Copy] The Journal of antimicrobial chemotherapy, Vol. 55, No. 3. (March 2005), pp. 333-340. by T. Whitehouse, J. A. Cepeda, R. Shulman, et al.L. Aarons, R. Nalda-Molina, C. Tobin, A. MacGowan, S. Shaw, C. Kibbler, M. Singer, A. P. Wilson posted to glycopeptide pharmacokinetics by lewista on 2008-11-20 15:05:41 as
	Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. [My Copy] The Journal of antimicrobial chemotherapy, Vol. 61, No. 1. (January 2008), pp. 85-90. by P. A. Moise, D. S. Smyth, N. El-Fawal, et al.D. A. Robinson, P. N. Holden, A. Forrest, G. Sakoulas posted to glycopeptide mrsa by lewista on 2008-11-18 14:12:43 as
	Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. [My Copy] Antimicrobial agents and chemotherapy, Vol. 52, No. 9. (September 2008), pp. 3315-3320. by T. P. Lodise, J. Graves, A. Evans, et al.E. Graffunder, M. Helmecke, B. M. Lomaestro, K. Stellrecht posted to glycopeptide mrsa by lewista on 2008-11-18 14:07:19 as
	Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. [My Copy] The Journal of antimicrobial chemotherapy, Vol. 62, No. 4. (October 2008), pp. 773-775. by J. I. Alós, A. García-Cañas, P. García-Hierro, F. Rodríguez-Salvanés posted to glycopeptide mrsa by lewista on 2008-11-18 14:02:01 as
	Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. [My Copy] The Journal of antimicrobial chemotherapy, Vol. 60, No. 4. (October 2007), pp. 788-794. by G. Steinkraus, R. White, L. Friedrich posted to glycopeptide mrsa by lewista on 2008-11-18 14:01:03 as
	Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia. [My Copy] The Journal of antimicrobial chemotherapy, Vol. 62, No. 5. (November 2008), pp. 1138-1141. by T. P. Lodise, C. D. Miller, J. Graves, et al.A. Evans, E. Graffunder, M. Helmecke, K. Stellrecht posted to glycopeptide mrsa by lewista on 2008-11-18 13:53:43 as
	Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06. [My Copy] The Journal of antimicrobial chemotherapy, Vol. 62 Suppl 2 (November 2008) by R. Hope, D. M. Livermore, G. Brick, M. Lillie, R. Reynolds, posted to glycopeptide mrsa mssa by lewista on 2008-11-18 13:38:09 as
	A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA) [My Copy] Annals of Clinical Microbiology and Antimicrobials, Vol. 6 (24 September 2007), 9. by Andreas Voss, Johan W. Mouton, Erika, et al.Ron G. Hendrix, Wil Goessens, Jan A. Kluytmans, Paul F. Krabbe, Han, Jacobus H. Sloos, Nefise Oztoprak, Robin A. Howe, Timothy R. Walsh posted to glycopeptide heteroresistance mrsa by lewista on 2008-11-17 08:21:58 as
	Unstable vancomycin heteroresistance is common among clinical isolates of methiciliin-resistant Staphylococcus aureus. [My Copy] Journal of clinical microbiology, Vol. 43, No. 5. (May 2005), pp. 2494-2496. by N. Plipat, G. Livni, H. Bertram, R. B. Thomson posted to glycopeptide heteroresistance mrsa by lewista on 2008-11-17 08:20:49 as
	Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). [My Copy] Journal of clinical microbiology, Vol. 46, No. 9. (September 2008), pp. 2950-2954. by M. J. Rybak, S. N. Leonard, K. L. Rossi, C. M. Cheung, H. S. Sadar, R. N. Jones posted to glycopeptide heteroresistance mrsa mssa by lewista on 2008-11-17 08:18:29 as
	Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages. [My Copy] Emerging infectious diseases, Vol. 10, No. 5. (May 2004), pp. 855-857. by R. A. Howe, A. Monk, M. Wootton, T. R. Walsh, M. C. Enright posted to glycopeptide heteroresistance mrsa by lewista on 2008-11-14 16:30:18 as
	A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. [My Copy] Journal of clinical microbiology, Vol. 45, No. 2. (February 2007), pp. 329-332. by M. Wootton, A. P. MacGowan, T. R. Walsh, R. A. Howe posted to glycopeptide heteroresistance mrsa by lewista on 2008-11-14 16:25:54 as
	Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. [My Copy] Journal of clinical microbiology, Vol. 44, No. 11. (November 2006), pp. 3883-3886. by G. Wang, J. F. Hindler, K. W. Ward, D. A. Bruckner posted to glycopeptide mrsa by lewista on 2008-11-14 15:56:21 as
	The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. [My Copy] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 44, No. 9. (1 May 2007), pp. 1208-1215. by F. C. Tenover, R. C. Moellering posted to glycopeptide mrsa by lewista on 2008-11-14 15:54:29 as
	Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. [My Copy] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 38, No. 4. (15 February 2004), pp. 521-528. by B. P. Howden, P. B. Ward, P. G. Charles, et al.T. M. Korman, A. Fuller, P. du Cros, E. A. Grabsch, S. A. Roberts, J. Robson, K. Read, N. Bak, J. Hurley, P. D. Johnson, A. J. Morris, B. C. Mayall, M. L. Grayson posted to glycopeptide heteroresistance mrsa by lewista on 2008-11-14 15:52:00 as
	Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. [My Copy] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 38, No. 3. (1 February 2004), pp. 448-451. by P. G. Charles, P. B. Ward, P. D. Johnson, B. P. Howden, M. L. Grayson posted to glycopeptide heteroresistance mrsa by lewista on 2008-11-14 15:42:41 as
	Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. [My Copy] Journal of clinical microbiology, Vol. 42, No. 6. (June 2004), pp. 2398-2402. by G. Sakoulas, P. A. Moise-Broder, J. Schentag, A. Forrest, R. C. Moellering, G. M. Eliopoulos posted to glycopeptide mrsa by lewista on 2008-11-14 15:35:54 as
	Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. [My Copy] The Journal of antimicrobial chemotherapy, Vol. 40, No. 1. (July 1997), pp. 135-136. by K. Hiramatsu, H. Hanaki, T. Ino, K. Yabuta, T. Oguri, F. C. Tenover posted to glycopeptide heteroresistance mrsa by lewista on 2008-11-10 13:00:40 as
	Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. [My Copy] The Journal of antimicrobial chemotherapy, Vol. 42, No. 2. (August 1998), pp. 199-209. by H. Hanaki, K. Kuwahara-Arai, S. Boyle-Vavra, R. S. Daum, H. Labischinski, K. Hiramatsu posted to glycopeptide heteroresistance mrsa by lewista on 2008-11-10 12:56:50 as

Note: You may cite this page as: http://www.citeulike.org/user/lewista/tag/glycopeptide

mrsa	51
glycopeptide	28
mssa	21
genomics	20
environment	17
epidemiology	12
heteroresistance	12
acinetobacter	9
pharmacokinetics	6
diagnostics	5
anthrax	4
crbsi	4
hcai	4
pji	4
prevention	4
tuberculosis	4
endocarditis	3
evolution	3
military	3
pcp	3
rifampicin	3
anaerobes	2
osteomyelitis	2
transplantation	2
aminoglycoside	1
beta-lactamase	1
cap	1
cdiff	1
cns	1
ecoli	1
fungal	1
influenza	1
lyme	1
norovirus	1
pneumonia	1
prophylaxis	1
quality	1
quorum	1
salmonella	1
sepsis	1
snp	1
stewardship	1
tdm	1
typing	1
yersinia	1

lewista's glycopeptide [28 articles] Export

lewista's tags